Halister News

(Bloomberg) -- Sanofi now expects FY16 Business EPS to grow between 3%-5% at constant FX vs broadly stable previously, barring unforeseen major adverse events.

• Starting a EU3.5b share repurchase program to be completed by end of 2017
• Co. to divest EU generics business within 12-24 months
• Cost savings now to be at least EU1.5b by 2018
• 3Q Global Business Unit Net Sales (at constant FX):
  • Genzyme: EU1.27b, up 17%
  • Diabetes and CV: EU1.59b, down 2.5%
  • General Medicines and Emerging Markets: EU4.37b, down 2.4%
  • Vaccines: EU1.8b, up 14%
  • Merial: EU624m, up 4%
• 3Q Net sales (aggregate): EU9.65b vs est. EU9.58b
• 3Q Business EPS: EU1.79 vs est. EU1.55
• 3Q Business net income: EU2.3b vs est. EU1.99b
• 3Q worldwide drug sales (Total Franchises):
  • Lantus: EU1.39b vs est. EU1.41b
  • Plavix: EU401m vs est. EU392m
  • Lovenox: EU404m vs est. EU416.9m
  • Fabrazyme: EU176m vs est. EU169.4m
  • Cerezyme: EU183m vs est. EU200.2m
  • Toujeo: EU167m vs est. EU164.1m
  • Aubagio: EU334m vs est. EU332.7m
  • Lemtrada: EU112m vs est. EU117.7m
  • Aprovel: EU174m vs est. EU152.7m
• NOTE: Yesterday, PREVIEW SANOFI 3Q: Limited Sales Growth, Forecast Likely Kept